J. Pirsch et al., Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: Pharmacokinetics and tolerability, J CLIN PHAR, 40(5), 2000, pp. 527-532
The tolerance and pharmacokinetics (PK) of tacrolimus (T) by the addition o
f mycophenolate mofetil (MMF) in stable kidney transplant patients (6/group
) on long-term tacrolimus-based therapy were investigated. Patients receive
d combination T and MMF therapy at three MMF doses: 1, 1.5, and 2 g/day adm
inistered twice daily. A 12-hour blood PK profile for T was obtained prior
to MMF dosing; concomitant 12-hour profiles for T mycophenolic acid (MPA),
and mycophenolic acid glucuronide (MPAG) were obtained after 2 weeks of adm
inistration. Tolerance was monitored through 3 months. The intra- and inter
group PK of T were variable. The mean AUC(0-12) of T for each group was inc
reased after 2 weeks of concomitant MMF administration, but the increase wa
s not statistically significant. Both drugs were well tolerated. Gastrointe
stinal events were of interest as such have been attributed to both T and M
MF. Events reported were diarrhea, nausea, dyspepsia, and vomiting. Other c
ommon adverse events were headache, hy pomagnesemia, and tremors. Most were
mild, although a few were considered to be moderate. There was no apparent
relationship between the incidence of any adverse event and MMF treatment
group. In the present study, the coadministration of T and MMF did not sign
ificantly alter T pharmacokinetics. (C) 2000 the American College of Clinic
al Pharmacology.